Skip to main content

Advertisement

SpringerLink
Log in

Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications

  • Review Article
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

We aimed to provide a meta-analysis of the factors affecting vitreomacular traction (VMT) resolution after ocriplasmin use. A comprehensive systematic review of the complications after ocriplasmin use for VMT and macular hole was also done.

Methods

A literature search in PubMed was performed for studies about ocriplasmin published before 30 June 2015. Then a meta-analysis of the factors affecting the VMT resolution after ocriplasmin use was done, providing the pooled odds ratios for each factor and 95 % confidence intervals (CIs). We also described the potential adverse events after ocriplasmin use in a systematic review.

Results

A total of 194 abstracts were screened and 19 eligible studies were included in the meta-analysis. Age <65 years, female gender, vitreomacular adhesion diameter <1500 μm, phakic lens status and epiretinal membrane absence were found as positive predictive factors for VMT resolution, while macular hole size <250 μm was significantly associated with macular hole closure at the meta-analytical level. Various complications after ocriplasmin use were reported by frequency, including mainly vitreous floaters, photopsias, visual acuity decrease, ellipsoid zone changes, subretinal fluid development, enlargement of macular hole, anterior segment changes and electroretinogram alterations. It has to be noted that significant methodological weaknesses were identified, such as the absence of control groups or lack of transparency in the recruitment process and the examination procedure.

Conclusions

It is important to carefully select patients for ocriplasmin injection, taking into account the various predictive factors for VMT resolution. Patients should be informed about the potential adverse events of ocriplasmin, although they mainly seemed to be transient and usually mild/moderate in severity, suggesting that ocriplasmin is a safe and effective new treatment alternative for VMT and macular hole. However, due to the limited study quality, the uncertainty concerning the efficacy of this new approach is increased.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sebag J (2009) Vitreous: the resplendent enigma. Br J Ophthalmol 93:989–991

    Article  CAS  PubMed  Google Scholar 

  2. Johnson MW (2005) Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 103:537–567

    PubMed  PubMed Central  Google Scholar 

  3. Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619

    Article  PubMed  Google Scholar 

  4. Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA (2013) Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 33:2003–2011

    Article  CAS  PubMed  Google Scholar 

  5. John VJ, Flynn HW Jr, Smiddy WE, Carver A, Leonard R, Tabandeh H, Boyer DS (2014) Clinical course of vitreomacular adhesion managed by initial observation. Retina 34:442–446

    Article  PubMed  Google Scholar 

  6. Dimopoulos S, Bartz-Schmidt KU, Gelisken F, Januschowski K, Ziemssen F (2015) Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy? Br J Ophthalmol 99:350–353

    Article  PubMed  Google Scholar 

  7. Mester V, Kuhn F (2000) Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 129:769–777

    Article  CAS  PubMed  Google Scholar 

  8. Kuppermann BD (2012) Ocriplasmin for pharmacologic vitreolysis. Retina 32:225–228

    Article  Google Scholar 

  9. Syed YY, Dhillon S (2013) Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 73:1617–1625

    Article  PubMed  Google Scholar 

  10. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, MIVI-TRUST Study Group (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615

    Article  CAS  PubMed  Google Scholar 

  11. Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, MIVI-TRUST Study Group (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122

    Article  PubMed  Google Scholar 

  12. Trikalinos TA, Trow P, Schmid CH (2013) Simulation-Based Comparison of Methods for Meta-Analysis of Proportions and Rates. Methods Research Report. (Prepared by the Tufts Medical Center Evidence-based Practice Center under Contract No. 290-2007-10055-I.) AHRQ Publication No. 13(14)-EHC084-EF. Rockville, MD: Agency for Healthcare Research and Quality www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed 09 Sep 2015.

  13. Louis TA (1991) Using empirical Bayes methods in biopharmaceutical research. Stat Med 10:811–827

    Article  CAS  PubMed  Google Scholar 

  14. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  PubMed Central  Google Scholar 

  15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:1–34

    Article  Google Scholar 

  16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012

    Article  CAS  PubMed  Google Scholar 

  17. Varma R, Haller JA, Kaiser PK (2015) Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol 133:997–1004

    Article  PubMed  Google Scholar 

  18. Gandorfer A, Benz MS, Haller JA, Stalmans P, Pakola SJ, Girach A, Kampik A, Toth CA, Jaffe GJ, MIVI-TRUST Study Group (2015) Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Retina 35:1151–1157

    Article  PubMed  Google Scholar 

  19. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, Kampik A (2009) Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 116:1349–1355

    Article  PubMed  Google Scholar 

  20. Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S (2010) Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 30:1122–1127

    Article  PubMed  Google Scholar 

  21. Beebe DC (2015) Understanding the adverse effects of ocriplasmin. JAMA Ophthalmol 133:229

    Article  PubMed  Google Scholar 

  22. Johnson MW, Fahim AT (2015) Understanding the adverse effects of ocriplasmin -reply. JAMA Ophthalmol 133:230

    Article  PubMed  Google Scholar 

  23. Tibbetts MD, Reichel E, Witkin AJ (2015) Understanding the adverse effects of ocriplasmin - reply. JAMA Ophthalmol 133:229–230

    Article  PubMed  Google Scholar 

  24. Hong J, Deng SX, Xu J (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2053

    PubMed  Google Scholar 

  25. Rao RC, Dlouhy BJ (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2053

    PubMed  Google Scholar 

  26. Huang J, Wen D, Wang Q (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2052–2053

    Article  PubMed  Google Scholar 

  27. Novack RL, Staurenghi G, Girach A, Narendran N, Tolentino M (2015) Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration. Ophthalmology 122:796–802

    Article  PubMed  Google Scholar 

  28. Maier M, Abraham S, Frank C, Feucht N, Lohmann CP (2015) Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole: First clinical experiences. Ophthalmologe 112:990–994

    Article  CAS  PubMed  Google Scholar 

  29. Steel DH, Sandinha MT, White K (2015) The Plane of Vitreoretinal Separation and Results of Vitrectomy Surgery in Patients Given Ocriplasmin for Idiopathic Macular Hole. Invest Ophthalmol Vis Sci 56:4038–4044

    Article  CAS  PubMed  Google Scholar 

  30. Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL (2015) Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Retina 35:1144–1150

    Article  CAS  PubMed  Google Scholar 

  31. Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P (2016) Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol 254:223–233

    Article  CAS  PubMed  Google Scholar 

  32. Reiss B, Smithen L, Mansour S (2015) Transient vision loss after ocriplasmin injection. Retina 35:1107–1110

    Article  CAS  PubMed  Google Scholar 

  33. Willekens K, Abegão Pinto L, Vandewalle E, Stalmans I, Stalmans P (2015) Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology. Retina 35:1135–1143

    Article  CAS  PubMed  Google Scholar 

  34. Meyer JC, Shah GK, Blinder KJ, Waheed NK, Reichel E, Stalmans P, Singer M, Tewari A (2015) Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 46:209–216

    Article  PubMed  Google Scholar 

  35. Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol 159:861–867

    Article  CAS  PubMed  Google Scholar 

  36. Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM (2015) Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes? Br J Ophthalmol 99:635–638

    Article  CAS  PubMed  Google Scholar 

  37. Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM (2015) Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 159:20–30

    Article  PubMed  Google Scholar 

  38. Chin EK, Almeida DR, Sohn EH, Boldt HC, Mahajan VB, Gehrs KM, Russell SR, Folk JC (2014) Incomplete vitreomacular traction release using intravitreal ocriplasmin. Case Rep Ophthalmol 5:455–462

    Article  PubMed  PubMed Central  Google Scholar 

  39. Itoh Y, Kaiser PK, Singh RP, Srivastava SK, Ehlers JP (2014) Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 121:2506–2507

    Article  PubMed  PubMed Central  Google Scholar 

  40. Miller JB, Kim LA, Wu DM, Vavvas DG, Eliott D, Husain D (2014) Ocriplasmin for treatment of stage 2 macular holes: early clinical results. Ophthalmic Surg Lasers Imaging Retina 45:293–297

    Article  PubMed  PubMed Central  Google Scholar 

  41. Knudsen VM, Kozak I (2014) A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction. Saudi J Ophthalmol 28:139–144

    Article  PubMed  PubMed Central  Google Scholar 

  42. Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monbl Augenheilkd 231:909–914

    Article  CAS  PubMed  Google Scholar 

  43. Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360

    Article  PubMed  Google Scholar 

  44. Kim BT, Schwartz SG, Smiddy WE, Doshi RR, Kovach JL, Berrocal AM, Moshfeghi AA, Fortun JA (2013) Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 44:334–343

    Article  PubMed  Google Scholar 

  45. Casswell E, Fernandez-Sanz G, Mitry D, Luk S, Zakir R (2014) Macular Hole Progression following Ocriplasmin Intravitreal Injection. Case Rep Ophthalmol Med 2014:403461

    PubMed  PubMed Central  Google Scholar 

  46. Chod RB, Goodrich C, Saxena S, Akduman L (2015) Lamellar macular hole after intravitreal ocriplasmin injection. BMJ Case Rep doi. doi:10.1136/bcr-2014-207810

    Google Scholar 

  47. Silva RA, Moshfeghi DM, Leng T (2014) Retinal breaks due to intravitreal ocriplasmin. Clin Ophthalmol 8:1591–1594

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Keller J, Haynes RJ (2015) Zonular Dehiscence at the Time of Combined Vitrectomy and Cataract Surgery After Intravitreal Ocriplasmin Injection. JAMA Ophthalmol 133:1091–1092

    Article  PubMed  Google Scholar 

  49. Barteselli G, Carini E, Invernizzi A, Ratiglia R, Viola F (2016) Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin. Acta Ophthalmol 94:160–162

    Article  Google Scholar 

  50. Han IC, Scott AW (2015) Sterile endophthalmitis after intravitreal ocriplasmin injection: report of a single case. Retin Cases Brief Rep 9:242–244

    Article  PubMed  Google Scholar 

  51. Chuo JY, Lee TY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DA (2006) Risk factors for posterior vitreous detachment: a case–control study. Am J Ophthalmol 142:931–937

    Article  PubMed  Google Scholar 

  52. Hilford D, Hilford M, Mathew A, Polkinghorne PJ (2009) Posterior vitreous detachment following cataract surgery. Eye 23:1388–1392

    Article  CAS  PubMed  Google Scholar 

  53. Reiss B, Smithen L, Mansour S (2015) Acute vision loss after ocriplasmin use. Retin Cases Brief Rep 9:168–169

    Article  PubMed  Google Scholar 

  54. Fahim AT, Khan NW, Johnson MW (2014) Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol 132:484–486

    Article  CAS  PubMed  Google Scholar 

  55. Freund KB, Shah SA, Shah VP (2013) Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye 27:773–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. DaCosta J, Younis S (2014) Transient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin. Drug Healthc Patient Saf 6:175–178

    Article  PubMed  PubMed Central  Google Scholar 

  57. Quezada Ruiz C, Pieramici DJ, Nasir M, Rabena M, Avery RL (2015) Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. Retin Cases Brief Rep 9:145–148

    Article  PubMed  Google Scholar 

  58. Johnson MW, Fahim AT, Rao RC (2015) Acute ocriplasmin retinopathy. Retina 35:1055–1058

    Article  PubMed  PubMed Central  Google Scholar 

  59. de Smet MD, Jonckx B, Vanhove M, van Calster J, Stalmans P, Stassen J (2010) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213

    Article  Google Scholar 

  60. Stalmans P, Girach A (2013) Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci 54:6620–6627

    Article  CAS  PubMed  Google Scholar 

  61. Thanos A, Hernandez-Siman J, Marra KV, Arroyo JG (2014) Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection. Retin Cases Brief Rep 8:330–332

    Article  PubMed  Google Scholar 

  62. Tibbetts MD, Reichel E, Witkin AJ (2014) Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol 132:487–490

    Article  PubMed  Google Scholar 

  63. Ziemssen F, Bartz-Schmidt KU, Dimopoulos S (2016) Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when? Graefes Arch Clin Exp Ophthalmol

  64. Stalmans P (2016) A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit). Graefes Arch Clin Exp Ophthalmol

Download references

Author information

Authors and Affiliations

  1. NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK

    Irini Chatziralli & Sobha Sivaprasad

  2. 2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 1, Rimini street, Haidari, 12462, Athens, Greece

    Irini Chatziralli, Paraskevi Xanthopoulou & Panagiotis Theodossiadis

  3. 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece

    George Theodossiadis

  4. Department of Ophthalmology, 401 Hellenic Army General Hospital, Athens, Greece

    Paraskevi Xanthopoulou

  5. Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece

    Paraskevi Xanthopoulou & Michael Miligkos

Authors
  1. Irini Chatziralli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Theodossiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paraskevi Xanthopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Miligkos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sobha Sivaprasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Panagiotis Theodossiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irini Chatziralli.

Ethics declarations

Conflict of interest

Irini Chatziralli, George Theodossiadis, Paraskevi Xanthopoulou, Michael Miligkos and Panagiotis Theodossiadis certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, or other equity interest), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Sobha Sivaprasad has received research grants, and attended Advisory Board meetings of Allergan, Bayer and Novartis.

Funding

No funding was received for this research.

Ethical approval

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chatziralli, I., Theodossiadis, G., Xanthopoulou, P. et al. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. Graefes Arch Clin Exp Ophthalmol 254, 1247–1256 (2016). https://doi.org/10.1007/s00417-016-3363-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-016-3363-5

Keywords

Search

Navigation